Corticosteroid therapy in critically ill patients with COVID-19: a multicenter, retrospective study

Table 3 Association between corticosteroid therapy and day-90 Mortality or SARS-CoV-2 RNA Clearance

	Day-90 mortality									SARS-CoV-2 RNA clearance
	Logistic regression			Cox proportional hazards regression model			Marginal structural model			Cox proportional hazards regression model			Marginal structural model
	OR	95%CI	p value	HR	95%CI	p value	OR	95%CI	p value	HR	95%CI	p value	OR	95%CI	p value
Corticosteroids versus no corticosteroids	0.15	0.00, 2.59	0.22	1.37	0.54, 3.47	0.51	1.37	0.93, 2.02	0.11	1.10	0.36, 3.37	0.86	0.85	0.63, 1.17	0.33
> 300 mg/day versus no corticosteroids^a	NA	NA	NA	0.62	0.12, 3.26	0.57	1.01	0.62, 1.64	0.98	0.81	0.10, 6.38	0.84	0.67	0.44, 1.02	0.062
≤ 300 mg/day versus no Corticosteroids^a	1.44	0.71, 2.96	0.31	1.42	0.94, 2.15	0.099	1.42	0.93, 2.17	0.1	0.91	0.22, 3.74	0.89	0.95	0.68, 1.34	0.78
> 3 day initiation versus no corticosteroids^b	1.08	0.56, 2.12	0.81	1.06	0.70, 1.59	0.8	1.11	0.75, 1.66	0.6	0.91	0.65, 1.25	0.55	0.85	0.62, 1.17	0.33
≤ 3 day initiation versus no corticosteroids^b	4.49	1.17, 17.25	0.025	3.89	1.94, 7.82	< 0.001	2.32	1.16, 4.65	0.017	0.26	0.13, 0.54	< 0.001	0.81	0.43, 1.52	0.5

HR hazard ratio, OR odds ratio, CI confidence interval, MSM marginal structural model, NA not available
^a300 mg/day means hydrocortisone equivalents per ICU day
^b> 3 day or ≤ 3 day means initiation of corticosteroids in more than 3 or less than 3 days after ICU admission

ISSN: 1364-8535